Royal Bank of Canada
PTHS

Royal Bank of Canada’s Pelthos Therapeutics PTHS Stock Holding History

Royal Bank of Canada’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+6
New +$154 ﹤0.01% 7877

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Royal Bank of Canada's PTHS Position: Q2 2026 in Review

Royal Bank of Canada opened a new position in Pelthos Therapeutics (PTHS) in Q2 2026: 6 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #7877 among its holdings.

24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Royal Bank of Canada held 6 shares of Pelthos Therapeutics worth $0 as of Q2 2026.
  • Pelthos Therapeutics was a new Royal Bank of Canada position in Q2 2026.
  • Pelthos Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7877 holding.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.